CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
超越血液系统恶性肿瘤的 CAR-T 细胞免疫治疗
英文原题：CAR T Cell Immunotherapy Beyond Haematological Malignancy.
查看英文原题
CAR T Cell Immunotherapy Beyond Haematological Malignancy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞表达一种经工程化改造以靶向特定抗原的合成受体，已展现出治疗血液系统恶性肿瘤的显著潜力。然而，其在血液系统恶性肿瘤之外的转化迄今尚不令人满意。在此，我们讨论CAR-T 细胞疗法针对实体瘤的近期挑战与改进：抗原异质性，其为针对传统单抗原特异性CAR-T 细胞提供了有效的逃逸机制；以及免疫抑制性肿瘤微环境，其提供了物理和分子屏障，分别阻止T细胞浸润并驱动T细胞功能障碍和增殖低下。此外，我们还讨论CAR-T 细胞在感染性疾病和自身免疫中的应用。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cells, which express a synthetic receptor engineered to target specific antigens, have demonstrated remarkable potential to treat haematological malignancies.
However, their transition beyond haematological malignancy has so far been unsatisfactory.
Here, we discuss recent challenges and improvements for CAR T cell therapy against solid tumors: Antigen heterogeneity which provides an effective escape mechanism against conventional mono-antigen-specific CAR T cells; and the immunosuppressive tumor microenvironment which provides physical and molecular barriers that respectively prevent T cell infiltration and drive T cell dysfunction and hypoproliferation.
Further, we discuss the application of CAR T cells in infectious disease and autoimmunity.
论文信息
- 作者
- Hupperetz C、Lah S、Kim H、Kim CH
- 单位
- Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.South Korea
- 文献类型
- 综述
- 期刊
- Immune network2022 Feb
- 原文标识
- PubMed 35291659 · DOI 10.4110/in.2022.22.e6
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →